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Abstract: Strategies for preventing ischemic complications during percutaneous coronary interventions (PCI) in the   
setting of acute myocardial infarction (AMI) have focused on the platelet surface-membrane glycoprotein (GP) IIb/IIIa  
receptor. The platelet GP IIb/IIIa receptor inhibitors, by blocking the final common pathway of platelet aggregation, have 
become a breakthrough in the management of acute coronary syndromes. Current adjuvant pharmacological therapy of 
AMI with aspirin, clopidogrel, unfractionated heparin (UH), and platelet GP IIb/IIIa inhibitors provides useful therapeutic 
benefits. Although the use of more potent antithrombin and antiplatelet agents during PCI in AMI has reduced the rate  
of ischemic complications, in parallel, the rate of bleeding has increased. Several studies have reported an association  
between bleeding after PCI and an increase in morbidity and mortality. Therefore, investigational studies have focused  
in pharmacological agents that would reduce bleeding complications without compromising the rate of major adverse  
cardiovascular events. Based on the results of several randomized trials, abciximab with UH, aspirin and clopidogrel have 
become a standard adjunctive therapy with primary PCI for AMI. However, some of the trials were done before the use of 
stents and the widespread use of thienopyridines. In addition, GP IIb/IIIa inhibitors use have been associated with throm-
bocytopenia, high rates of bleeding, and the need for transfusions, which increase costs, length of hospital stay, and mor-
tality. On the other hand, in the stent era, bivalirudin, a semi-synthetic direct thrombin inhibitor, has recently been shown 
to provide similar efficacy with less bleeding compared with unfractionated heparin plus platelet GP IIb/IIIa   
inhibitors in AMI patients treated with primary PCI. The impressive results of this recent randomized trial and other  
observational studies make a strong argument for the use of bivalirudin rather than heparin plus GP IIb/IIIa inhibitors for 
the great majority of patients with AMI treated with primary PCI. However, some controversial results and limitations in 
the studies with bivalirudin exert some doubts in the future widespread use of this drug. 
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INTRODUCTION 
  The prevalence of patients who have survived acute 
myocardial infarction (AMI) is estimated at 15 million. 
These patients are at high risk to develop additional acute 
events. The pathophysiology of acute coronary syndromes is 
characterized by disruption of atherosclerotic plaques, acti-
vation and aggregation of platelets, and formation of an arte-
rial thrombus [1]. Thrombus formation can result in either 
transient or persistent occlusion. Common antiplatelet agents 
such as aspirin and clopidogrel, and, in part, antithrombin 
agents such as heparin, act by inhibiting different pathways 
of platelet activation. This may account for the limited abil-
ity of these agents to prevent platelet aggregation, since other 
avenues of activation are left undisturbed [2]. Heparin only 
inhibits thrombin-induced platelet aggregation but may 
stimulate aggregation initiated by other agonists [3, 4]. 
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  The critical role of glycoprotein (GP) IIb/IIIa receptors as 
final common pathway for platelet aggregation suggests the 
possibility that antagonize this receptor may be the most 
effective for preventing platelet aggregation and, therefore, 
thrombosis. Regardless of the stimulus for platelet activa-
tion, GP IIb/IIIa antagonists inhibit thrombosis by preventing 
fibrinogen from binding to the platelet GP IIb/IIIa receptor, 
the final common pathway of platelet aggregation [5-8]. 
Platelets are known to play an important role in the patho-
genesis of acute coronary syndromes [9-12]. However, the 
high levels of platelet inhibition attainable with GP IIb/IIIa 
antagonists have failed to dramatically improve clinical out-
comes outside the scenario of percutaneous coronary inter-
vention (PCI). On the other hand, despite the success of ab-
ciximab in preventing ischemic events after PCI, the use of 
intravenous, small-molecule GP IIb/IIIa antagonist, and the 
intention to broaden the clinical indication have produced 
varied results. Mechanisms contributing to these heterogene-
ous outcomes may include the possibility of prothrombotic 
events, as well as, normal variation in platelet or receptor 
number, differences in receptor activity, and interpatient 
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intention to broaden the clinical benefits obtained with en-
dovenous GP IIbIIIa inhibitors to oral GP IIbIIIa inhibitors 
as adjuvant therapy of PCI failed to reach clinical relevance; 
therefore, they were abandoned from this therapeutic sce-
nario. 
  Based on the results of several randomized trials, abcixi-
mab with unfractionated heparin (UH) has become a stan-
dard adjunctive therapy with primary PCI for AMI, and GP 
IIb/IIIa inhibitors are used in the great majority of patients 
treated with primary PCI [13]. However, some of the trials 
were done before the use of stents and the widespread use of 
thienopyridines. In addition, GP IIb/IIIa inhibitors use have 
been associated with thrombocytopenia, high rates of bleed-
ing, and the need for transfusions, which increase costs, 
length of hospital stay and mortality. On the other hand, in 
the stent era, bivalirudin, a semi-synthetic direct thrombin 
inhibitor, has recently been shown to provide similar effi-
cacy with less bleeding compared with UH plus platelet GP 
IIb/IIIa inhibitors in elective PCI, in PCI for non-ST eleva-
tion acute coronary syndromes, and in AMI treated with 
primary PCI [9–13]. The results of these recent randomized 
trials and other observational studies make a strong argument 
for the use of bivalirudin rather than UH plus GP IIb/IIIa 
inhibitors for the great majority of patients with AMI treated 
with primary PCI. However, some controversial results and 
limitations in the studies with bivalirudin exert some doubts 
in the future widespread use of this drug. Therefore, this re-
view will emphasize the actual role of these platelet GP 
IIb/IIIa inhibitor agents in the stent and thienopyridine era, in 
the light of recent randomized trials and observational stud-
ies with bivalirudin in the adjunctive therapy of AMI in the 
setting of primary PCI. 
ROLE OF PLATELETS IN AMI 
  Thrombosis is often regarded as the pathologic extension 
of the normal haemostatic process. Under normal physiol-
ogic conditions, platelets are essencially inert; their adhesion 
to the subendothelial matrix is prevented by an intact vascu-
lar wall. The chief function of platelets is to coordinate with 
vascular endothelium and soluble plasma factors in the hae-
mostatic process [6]. In response to vessel trauma, platelets 
spontaneously adhere to newly exposed adhesive proteins 
forming a protective monolayer of cells. These platelets are 
activated very rapidly by agonists such as thrombin, colla-
gen, adenosine diphosphate, and thromboxane A2, causing 
morphologic changes and release of materials from stored 
vesicles. The constituents of the granules are involved 
mainly in the further activation of more platelets and the 
propagation of the haemostatic process [14-17]. 
  Plaque rupture occurs when the fibrous cap of the plaque 
is disrupted by physical stresses and either tears or is re-
moved completely. When the endothelial intima is inter-
rumpted, substances such as collagen, von Willebrand factor, 
fibronectin or vitronectin are exposed to circulating platelets 
and plasma coagulation factors [16, 17]. This process of 
platelet adhesion forms a monolayer of cells over the endo-
thelial lesion and specific agonists induce platelet vesicle 
secretion and aggregation. The final common pathway of all 
agonist-receptor interactions is the activation of a specific 
receptor responsible for platelet aggregation. This receptor, 
the GP IIb/IIIa is active only after the platelet has been 
stimulated and consequently after its intracellular calcium 
concentration has increased. The GP IIbIIIa is found only on 
cells of megakaryocytic origin and has a high affinity for the 
tripeptide sequence arginine-glycine-aspartic acid (RGD), 
which is found in fibrinogen, von Willebrand factor, fi-
bronectin and vitronectin [14, 15]. Primarily because of its 
high concentration in the plasma, fibrinogen is the primary 
polypeptide involved in platelet aggregation. Because fi-
brinogen is a divalent dimer, it is able to link adjacent plate-
lets. The presence of atherosclerotic vascular disease highly 
correlates with the development of platelet thrombi. Once 
formed, the thrombus may partially or totally occlude a ves-
sel, resulting in alteration of blood flow and tissue ischemia 
or necrosis. The atherosclerotic process involves the primary 
progression of growth of multifocal intimal lesions from 
fatty streaks to fibrous plaque. Lipid-filled foam cells invade 
the smooth muscle-collagen cap consequently reducing its 
strength. Advanced plaques may also contain a sizable pool 
of extracellular cholesterol within the plaque’s core. These 
weak, yellow plaques with high lipid content are particularly 
inclined to rupture. The damage to the endothelium also dis-
rupts production of endogenous vasodilators and antiplatelet 
agents such as, nitric oxide and prostacyclin [1, 4]. 
  After disruption of a thin cap of a plaque, some plaques 
may heal from the fissure, whereas, in others mural thrombi 
may develop and project into the artery lumen. These 
thrombi have a high platelet component, which causes the 
clot to appear white on coronary angioscopic examination. 
The intraluminal plaques may transiently reduce coronary 
flow leading to the ischemic condition of the acute coronary 
syndrome, or they may break up into microemboli, causing 
focal areas of necrosis and possible arrhythmias [2, 3]. If the 
intraluminal clot grows rapidly, it may not allow time for the 
development of collateral flow, predisposing the patient to 
an AMI. In patients who survive an episode of occlusive 
thrombus, a natural fibrinolytic reaction normally ensues. 
Plasminogen is converted to plasmin, which breaks down the 
fibrinogen and fibrin components of the thrombus restoring 
distal flow [6-8]. However, usually a high grade lumen 
stenosis remains, which sets the background for further 
events. In addition, fibrin debris that remains may contribute 
to further stenosis or possible total occlusion. 
  Therefore, it is very important to consider the role of 
platelets in AMI in order to prevent activation and further 
aggregation of platelets. The efficacy of acetylsalicylic acid 
(aspirin), as an antiplatelet agent has been thoroughly inves-
tigated, and even today it remains the most widely used and 
cost-efficient drug in the prevention of platelet aggregation. 
Ticlopidine, clopidogrel, and prasugrel, potent drugs with 
demonstrated antithrombotic properties in the prevention of 
ischemic diseases, have a much higher cost which precludes 
their widespread general use. Limitations in the use of these 
drugs have provided the impulse for the search for better 
antiplatelet drugs. Common antiplatelet agents act by inhibit-
ing different pathways of platelet activation. This may ac-
count for the limited ability of these agents to prevent plate-
let aggregation, since other avenues of activation are left 
undisturbed. In theory, a drug able to inhibit all of the ago-
nists of platelet activation would necessarily be more effec-
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PLATELET GP IIB/IIIA RECEPTOR ANTAGONISTS 
IN AMI 
  Platelet aggregation is mediated by the GP IIb/IIIa recep-
tor, a member of the integrin family of membrane-bound 
adhesion molecules. Integrins are defined as subunit recep-
tors composed of an alfa-subunit (GP IIb) and a beta-subunit 
(GP IIIa) capable of mediated adhesive interactions between 
cells matrix. It is the chief receptor responsible for platelet 
aggregation by its ability to bind soluble fibrinogen, which 
forms bridges between platelets leading ultimately to throm-
bus formation. Platelet GP IIb/IIIa receptor is distributed 
widely on platelet surfaces. There are an estimated 40,000 to 
80,000 GP IIb/IIIa receptors per platelet, making it the most 
numerous receptors on the platelet membrane surface [18-
20]. However, this receptor remains unable to bind fibrino-
gen unless the platelet is first stimulated by agonists and un-
dergoes a conformational change [20]. 
  The platelet GP IIb/IIIa receptor is the first integrin to be 
identified and has served as a model for characterization of 
other integrins. It is a heterodimer of 2 subunits. The 2 
subunits of GP IIb/IIIa are encoded by separate gens on the 
long arm of chromosome-17. Although each subunit is syn-
thesized separately, the receptor heterodimer must be assem-
bled within the megakaryocyte for either subunit to be ex-
pressed [20]. It has been demonstrated by electron micros-
copy that the receptor is composed of a globular head and 2 
flexible tails that are imbebbed in the platelet membrane [21-
23]. The GP IIb/IIIa domains responsible for binding adhe-
sive proteins have been identified and in general are charac-
terized by their ability to recognize the peptide sequence 
RGD. The RGD recognition sequence was originally de-
scribed for fibronectin but is now known to be present in 
fibrinogen, von Willebrand factor, vitronectin and throm-
bospondin [24]. If 2 activated platelets with functional GP 
IIb/IIIa receptors each bind the same fibrinogen molecule, a 
fibrinogen bridge is created between platelets. A thrombus 
forms when this process of aggregation is repeated thousands 
of times. Since GP IIb/IIIa receptor is unique to platelets   
and is the final common pathway for platelet aggregation by 
all agonists, these factors make these receptors a favorable 
target for therapeutic pharmacologic blockade [21-23]. 
ABCIXIMAB (Murine Monoclonal Antibodies 7E3) 
  In 1985, Coller produced a mouse monoclonal antibody 
against the GP IIb/IIIa integrin receptor [23]. The Coller 
antibody, termed abciximab or 7E3, has a molecular weight 
of 47.6 kD and exhibits both a high-affinity and absolute 
specificity for the GP IIb/IIIa receptor, 2 properties that 
make 7E3 an attractive agent for the blocking adhesive pro-
teins [24-27]. Abciximab shows a high binding affinity for 
the GP IIb/IIIa receptor in either the active or inactive state 
with additional activity against the vitronectin receptor and 
possibly MAC-1 [28, 29]. The vitronectin receptor plays a 
role in cell adhesion, migration and proliferation. The vi-
tronectin receptor blockade can prevent smooth muscle cell 
hyperplasia, and MAC-1 inhibition can prevent stimulated 
monocyte-induced smooth muscle cell apoptosis. Abciximab 
has almost no renal excretion, but is cleared rapidly from the 
plasma. However, it is detectable bound to circulating plate-
lets for at least 21 days [30, 31]. 
SMALL-MOLECULE AGENTS 
  Eptifibatide is a cyclic heptapeptide based upon the Lys-
Gly-Asp (KGD) amino acid sequence. It has a molecular 
weight of 0.832 kD and 50% renal excretion [32]. Tirofiban 
is tyrosine-derivative nonpeptide mimetic with molecular 
weight of 0.495 kD and 40-70% renal excretion [33]. Lami-
fiban is also nonpeptide mimetic with a molecular weight   
of 0.468 kD and 90% renal excretion [34]. Compared with 
abciximab, these small-molecule agents demonstrate exclu-
sive specificity for GP IIb/IIIa receptor, have less binding 
affinity, shorter duration of biological effect beyond the   
administration period and predominantly undergo renal   
excretion. 
  Differences in pharmacology have been identified   
between the agents. Abciximab is derived from the mono- 
clonal antibody 7E3, while the small molecule antagonists  
are modeled on the alpha-chain (RGD) and the gamma-chain  
(KQADV) aminoacid recognition sequences in fibrinogen.   
The inhibition of fibrinogen binding to GP IIb/IIIa receptors  
is competitive for the small molecule antagonists and non- 
competitive with abciximab due to its high affinity and slow  
dissociation rate. Recent findings have made it clear that the  
different agents interact with separate regions corresponding  
to, or located close to, the fibrinogen-binding sites on   
platelet GP IIb/IIIa receptor. Interaction with different sites  
may explain their differential ability to inhibit platelet- 
mediated thrombin generation; abciximab is the most potent,  
tirofiban intermediate and eptifibatide is the weakest [31-33].  
In addition to differences in their interaction sites on the   
GP IIb/IIIa receptor, the small molecules and abciximab   
differ in their binding specificity. Tirofiban and eptifibatide  
are highly specific for GP IIb/IIIa, abciximab is less so.   
Recently, a prospective, randomized trial comparing the 
platelet effects of abciximab, tirofiban and eptifibatide,   
demonstrated similar levels of inhibition of platelet aggrega- 
tion, similar reduction in the platelet-monocyte interaction   
and similar mean alpha-degranulation, as a measure of   
antagonist-induced platelet activation [35]. Although, all of  
these agents reduce ischemic risk to a different level [34,   
35], there does seem to be heterogeneity among the drugs  
with regard to the magnitude and durability of treatment   
effect, at least in the setting of PCI. Apparent variability   
among agents in efficacy may be due to pharmacodynamics  
of receptor binding, with the slow dissociation of abciximab  
contrasting with the rapid reversibility of other agents. Addi- 
tionally, the nonspecific blockade by abciximab of both the  
IIb/IIIa receptor and the vitronectin receptor may theoreti- 
cally provide an advantage over the specific agents. The   
suppression of platelet-mediated thrombin generation with   
dual receptor inhibition is more complete in comparison with  
inhibition of either receptor alone. 
  Platelet GP IIb/IIIa antagonist are potent platelet inhibi-
tors, and thus their efficacy is greatest in conditions associ-
ated with acute platelet-mediated thrombosis, specifically 
AMI. Attemps to expand the therapeutic indication of GP 
IIb/IIIa antagonists to other conditions associated with plate-
let-mediated thrombosis outside PCI have been less fruitful 
than expected [31-33]. 138    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Osmar Antonio Centurión 
PLATELET GP IIB/IIIA ANTAGONIST USE IN THE 
SETTING OF PRIMARY PCI DURING AMI 
  In the 1990s, platelet GP IIb/IIIa inhibitors were intro-
duced as adjunctive therapy for elective PCI and were soon 
shown to be effective with primary PCI in the setting of 
AMI. The greatest magnitude of clinical benefit with these 
GP IIb/IIIa receptor antagonist agents is achieved in patients 
undergoing primary PCI, wherein the timing of plaque injury 
and the role of acute platelet aggregation are precisely de-
fined. Two large randomized international trials demon-
strated the unquestionable superiority of stents over balloon 
angioplasty, mainly because of significantly less incidence of 
restenosis and reduced need for repeat revascularization [36, 
37]. However, stenting activates expression of the GP 
IIb/IIIa receptor on the platelet surface and predisposes to 
coronary thrombus, which is partly reflected by the clinical 
syndrome known as subacute thrombosis [38]. The use of a 
metal prosthetic device during the procedure may also lead 
to mural thrombus inside the stent, embolize atherosclerotic 
material or fragmented thrombus, and predispose to deeper 
arterial wall trauma and platelet activation because of high 
pressure inflation. These pathophysiological triggers may be 
more adequately and effectively controled with the associa-
tion of platelet GP IIb/IIIa receptor antagonists to stenting. 
The platelet GP IIb/IIIa receptor antagonists have shown that 
they can, not only, maintain patency of the recanalized ves-
sel, but also avoid emboli of platelet aggregates to the distal 
arterial circulation [39]. The addition of platelet GP IIb/IIIa 
receptor inhibition therapy to PCI resulted in several benefi-
cial effects (Table 1). In an experimental study of stenting 
and abciximab, it was demonstrated that abciximab treatment 
reduced platelet thrombus formation area by 89%, but did 
not prevent the deposition of a discontinuous monolayer of 
platelet, demonstrating that abciximab blocks platelet to 
platelet interactions, but not platelet adhesion [40]. The 
authors of this experimental study proposed that stent inser-
tion leads to a reduction in blood flow inmediately adjacent 
to the wall, which favors thrombin generation and the devel-
opment of a fibrin network that can trap the nearby layer of 
stagnant blood. The most plausible explanation for abcixi-
mab’s effect is that it decreases platelet thrombus formation 
at the sites where the stent struts contact the vessel wall and 
thus decreases thrombin generation and fibrin formation. 
There was also a significant smaller platelet thrombus at the 
site of stent insertion which explains the protective effect of 
abciximab on the microcirculation [40]. A study designed to 
assess endothelium-dependent vasomotion after coronary 
stenting plus abciximab demonstrated that abciximab pre-
serves the coronary blood flow response to acetylcholine 
after coronary stenting [41]. Acetylcholine-mediated in-
crease in coronary blood flow was impaired after stenting, 
however when it was associated to abciximab there was   
a significantly superior response than in the stent alone 
group [41]. The preservation of microvascular endothelial 
function may help explain the beneficial clinical effects   
of GP IIb/IIIa recetor antagonists in patients undergoing   
primary PCI [41]. 
  The role of periprocedural GP IIb/IIIa inhibition in the 
setting of primary PCI during AMI was established by sev-
eral randomized, placebo-controlled trials enrolling near 
4,000 patients [42-46]. Prompt restoration of both epicardial 
blood flow and myocardial microcirculation are the goals of 
reperfusion strategies in AMI. As adjunctive therapy for 
primary PCI, the primary objective of the randomized trials 
with intravenous GP IIb/IIIa inhibitors was to reduce a 30-
day ischemic composite end point (death, MI, urgent revas-
cularization) (Table 2). The most compelling support for 
platelet GP IIb/IIIa inhibition therapy comes from the ab-
ciximab trials. They have demonstrated a clinically impor-
tant reduction in early ischemic events, sustained beneficial 
effects at long-term follow-up, and benefits that extends 
similarly to all interventional devices, lesion complexities 
and patient acuities. Specifically, there have been 5 large 
randomized placebo controlled trials evaluating abciximab 
with UH as adjunctive therapy with primary PCI for AMI 
[42-46]. All 5 trials have shown improved efficacy with ab-
ciximab with a reduction in major adverse cardiac events 
driven primarily by a reduction in urgent target vessel revas-
cularization (Table 2). A meta-analysis of these 5 trials 
(RAPPORT, ISAR II, ADMIRAL, CADILLAC and ACE) 
plus 3 smaller trials by De Luca et al. [47] with a total of 
3,949 patients treated with primary PCI found that abcixi-
mab reduced 30-day and 6 to 12-month mortality (2.4% vs 
3.4%, OR 0.68 [0.47–0.99], P=0.047 and 4.4% vs 6.2%, OR 
0.69 [0.52–0.92], P=0.01) and reduced 30 day reinfarction 
rates (1.0% vs 1.9%, OR 0.56 [0.22–0.94], P=0.03) with no 
difference in bleeding (4.7% vs 4.1%, P=0.36) [47]. Another 
meta-analysis of only 3 of these randomized trials (ISAR II, 
ADMIRAL, CADILLAC) on stent placement in AMI with 
either adjunctive abciximab or placebo was described [48]. 
Adjunctive use of abciximab in stent treated patients resulted 
in an event rate of 12% vs 16.6% without abciximab (OR 
0.70; 95% CI 0.54-0.92, p<0.001). Thus, abciximab pre-
vented 44 major events per 1000 patients treated. It was con-
cluded that optimal mechanical reperfusion in AMI is pro-
vided by stent placement and GP IIb/IIIa inhibitors use, with 
a 30% odd reduction in the composite end point. Results 
from a substudy of the ADMIRAL trial have demonstrated 
that even in very high risk patients in cardiogenic shock 
there is a beneficial effect. Death was reduced by 57% with 
abciximab compared with patients with placebo (9.1% vs 
21.4%, NS) [49]. Considering that there were only 25 pa-
tients with shock, very small sample size, these results must 
be interpreted cautiously. Therefore, these results would 
need further confirmation in a specific trial. Two recent ob-
servational, non-randomized studies have shown that treat-
ment with platelet GP IIb/IIIa inhibitor abciximab during 
angioplasty resulted in improved outcome of patients with 
shock complicating AMI [50, 51]. Similar results were ob-
tained with eptifibatide in this subgroup of high risk patients. 
Although, only 25% of the the shock-patients underwent 
PCI, a retrospective sub-study of the PURSUIT trial has 
shown that patients treated with eptifibatide seemed to have 
reduced adjusted odds of 30-day death from shock 
(OR=0.51, 95% CI 0.28-0.94; p=0.03), suggesting a possible 
salutary effect of platelet GP II/b/IIIa blockade during shock 
[52]. Since this finding is derived from a post hoc analysis it 
should also be verified in specifically designed studies. 
  Based on these data, abciximab with UH has become a 
standard adjunctive therapy with primary PCI for AMI and 
GP IIb/IIIa inhibitors are used in the great majority of pa-
tients treated with primary PCI. However, some of the trials 
were done before the use of stents and the widespread use of Current Role of GP IIb/IIIa Inhibitors in AMI  The Open Cardiovascular Medicine Journal, 2010, Volume 4    139 
thienopyridines. For example, the largest trial, CADILLAC 
[45], which had a 2x2 randomization to abciximab vs pla-
cebo and stenting vs balloon angioplasty, found that the re-
duction in the 30-day major adverse cardiovascular events 
rate with abciximab was more pronounced in patients as-
signed to the balloon angioplasty group (4.3% vs 8.1%, RR 
47%, p=0.01) than in those assigned to stenting (4.2% vs 
5.3%, RR 21%, NS). Therefore, these findings highlight the 
beneficial effects of platelet GP IIb/IIIa receptor blockade in 
AMI patients undergoing primary balloon angioplasty, 
probably due to the less internal luminal diameter achieved 
with this procedure compared with stenting. Therefore, this 
trial found that abciximab reduced the major cardiovascular 
events in patients treated with ballon angioplasty but not in 
patients treated with stenting, although it did reduce the fre-
quency of stent thrombosis [45]. Consequently, there has not 
been universal agreement about the importance of abciximab 
with primary PCI in the era of clopidogrel and stenting. The 
2004 ACC/AHA Guidelines for AMI treatment states that 
the use of abciximab with primary PCI for AMI is reason-
able (Class IIa indication) [53]. This has not been changed in 
the recent 2007 guidelines update [54]. 
Table 1.  Beneficial Effects with the Addition of Platelet GP 
IIb/IIIa Receptor Inhibitor Therapy to Primary PCI  
1  Inhibition of platelet aggregation 
2  Reduced platelet-mediated thrombin generation 
3  Reduced platelet released vasoactive agents 
4  Reduced platelet-mediated clot retraction 
5  Reduced intimal hyperplasia in response to vascular injury 
6  Short- and long-term reduction in ischemic complications 
7  Improved microcirculatory function 
8  Recovery of myocardial function 
9  Reduced long-term mortality 
COMPARISON OF GP IIB/IIIA RECEPTOR   
ANTAGONISTS WITH BIVALIRUDIN IN AMI: IS IT 
THE END OF AN ERA? 
  A combination of antithrombotic and antiplatelet thera-
pies with UH, aspirin, thienopyridine, and GP IIb/IIIa recep-
tor inhibitors has been used to reduce the incidence of 
ischemic complications during primary PCI in AMI. As Gib-
son stated, there is a growing body of AMI literature sup-
porting a “union in reperfusion”: the use of pharmacologic 
agents to quickly open both the artery and the microvascula-
ture and the use of adjunctive interventions to further im-
prove flow and keep arteries open [55]. There are several 
factors to consider in the safety profile of the platelet GP 
IIb/IIIa receptor inhibitors. Platelet inhibition of >80% is 
required for maximum efficacy [56]. Failure to achieve these 
high levels of inhibition is associated with lack of protection 
from acute events. Moderate levels of platelet inhibition not 
only lack efficacy but are associated with a paradoxical in-
crease in ischemic complications due to the unmasking an-
tagonist-induced prothrombotic and proinflammatory effects 
[56-59]. During an abciximab infusion, more than 25% of 
patients are less than 80% inhibited increasing the possibility 
of thrombotic, counterregulatory events. The reduction of 
bleeding complications in the PCI plus GP IIb/IIIa antago-
nists trials demonstrates that reduction of concomitant hepa-
rin doses, as well as early vascular sheath removal amelio-
rate excess hemorrhagic risk in this setting. For patients who 
develop refractory or life-threatening bleeding, the anti-
platelet effect of abciximab may be reversed by discontinua-
tion of drug infusion and by platelet transfusion after the 10 
to 30 min required for clearence of circulating drug. Platelet 
transfusions should rarely be necessary with rapidly reversi-
ble agents such as eptifibatide and tirofiban, and in fact, 
might not be expected to be effective during the 2 h required 
for elimination of these agents from the circulating plasma 
phase [60]. Thrombocytopenia occurs infrequently with GP 
IIb/IIIa inhibition but may be precipitous and profound 
(platelet count of <50,000 mm
3) [60]. Therefore, platelet 
count should be measured early (within the first 2 to 4 h) 
after administering these agents and followed for the dura-
tion of therapy. Pseudothrombocytopenia is the cause of 
more than one third (36%) of low platelet counts in patients 
undergoing PCI who are treated with abciximab. Pseudo-
thrombocytopenia is a benign laboratory condition that does 
not increase the risk of bleeding, stroke, transfusion re-
quierements or the need for repeat revascularization. Be-
sides, it does not require specific therapy. Therefore, it is 
important to recognize this condition so that the beneficial 
effects of abciximab are not lost by premature termination of 
therapy [60]. In this regard, it is important to note that due to 
its murine origin, abciximab elicits an immune response in 
the form of IgG antibody production, termed the human an-
tichimeric antibody (HACA), in 7% of patients within the 
first month after initiation of therapy. This does not occur 
with the small molecule antagonists. Abciximab readminis-
tration in this situation is safe and does not result in an aller-
gic response or any increase in adverse events, although, 
increased levels of thrombocytopenia are seen. The presence 
or absence of a positive HACA titer was not predictive of a 
lack of clinical effectiveness, development of thrombocy-
topenia, or other sequelae in patients undergoing readminis-
tration [60]. Thus, overall side effects are similar with the 
different agents and usually not a major clinical problem. 
  Although the use of more potent antithrombin and anti-
platelet agents during PCI has reduced the rate of peri and 
post-procedural ischemic complications, in parallel, the rate 
of bleedings has increased [61]. Of importance, numerous 
studies have reported an association between bleeding after 
PCI and an increase in short- and long-term morbidity and 
mortality [61-63]. Bivalirudin, a direct thrombin inhibitor, 
was developed as an antithrombin agent for patients under-
going PCI with the hypothesis that it would reduce bleeding 
complications without compromising the rate of ischemic 
events compared with UH plus GP IIb/IIIa inhibitors. Con-
sistently, trials performed in various clinical settings, from 
stable angina to acute coronary syndrome, have demon-
strated that the strategy of bivalirudin with provisional GP 
IIb/IIIa inhibitors was superior when compared with UH 
with systematic GP IIb/IIIa inhibitors in regard to reduction 
in bleeding complications without any increase in the rate of 
ischemic events [10-12]. The recent Harmonizing Outcomes 
with RevascularIZatiON and stents in ST Elevation Myocar-140    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Osmar Antonio Centurión 
dial Infarction (HORIZON STEMI) trial expanded these 
findings to primary PCI in AMI [13].  
  Bivalirudin is a semi-synthetic 20 amino-acid polypep-
tide derived from native hirudin [13]. This compound binds 
specific for unbound and bound thrombin at a 1:1 ratio. It 
has potential advantages over UH (Table 3) [13]. The HO-
RIZONS Trial evaluated bivalirudin in AMI patients treated 
with primary PCI [13]. Bivalirudin, compared with UH plus 
platelet GP IIb/IIIa inhibitors, resulted in less major bleeding 
(4.9% vs 8.3%, P<0.001) (Fig. 1A), and similar rate of major 
adverse cardiovascular events at 30 days (5.4% vs 5.5%, 
P=0.95) (Fig. 2A). The primary endpoint, a composite of 
major adverse cardiovascular events or major bleeding (net 
adverse clinical events), was significantly less with bivali-
rudin (9.2% vs 12.1%, P=0.005) (Fig. 3). Furthermore, 30-
day mortality was significantly less with bivalirudin (2.1% 
vs 3.1%, P=0.047), and there was less thrombocytopenia 
(0.5% vs 1.1%, P=0.02). The frequency of stent thrombosis 
in the first 24 h after PCI was greater in the bivalirudin group 
(1.3% vs 0.3%, P <0.001). However, at 30 days, there were 
no significant differences between groups (2.5% vs 1.9%, 
P=0.30). The HORIZONS trial [13] is the first to show a 
significant reduction in mortality with any adjunctive ther-
apy used with primary PCI in AMI patients. However, this 
result could have occurred by chance and should be consid-
ered with caution, because mortality was not a primary or 
secondary endpoint. In addition, the study was not powered 
to detect differences in mortality between both groups. Nev-
ertheless, there are certain factors that could explain this 
mortality difference. Major bleeding complications in pa-
tients with acute coronary syndromes treated with PCI have 
been shown to be strong predictors of subsequent stent 
thrombosis, other ischemic events and death [64, 65]. 
Moreover, major bleeding has been shown to be the strong-
est predictor of 30-day mortality in PCI-treated patients with 
acute coronary syndromes, even stronger than periprocedural 
AMI [64, 65]. Major bleeding can contribute to mortality 
because of mortality from the bleeding event itself, the need 
for transfusions, and the need for discontinuation of anti-
platelet and anticoagulant therapy which may predispose to 
stent thrombosis and other ischemic events. Blood transfu-
sions are associated to significantly increased morbidity and 
mortality, increased infections, and increased hospital stay 
and costs [66, 67]. Thrombocytopenia is also associated with 
worse outcomes, and the reduction in thrombocytopenia with 
bivalirudin may also contribute to lower mortality. 
Table  3.  Potential Advantages of Bivalirudin Over Unfrac-
tionated Heparin 
1  Bivalirudin has more predictable pharmokinetics 
2  It is not inactivated by PF4 
3  It does not require any cofactor for activity. 
4  It is not inhibited by plasma proteins. 
5  It does not activate platelets. 
6  It is not associated with thrombocytopenia. 
 
  The results of HORIZONS trial [13] make a strong ar-
gument for the use of bivalirudin rather than UH plus GP 
Table 2.  Randomized Trials Comparing 30-Day Outcomes with Abciximab vs Placebo in Primary PCI for Acute Myocardial  
Infarction 
  Abciximab  Placebo  P 
RAPPORT (42)  (n=241)  (n=242)   
Urgent TVR  1.7%  6.6%  p<0.006 
Composite 5.8%  11.2%  p<0.03 
ADMIRAL (43)  (n=149)  (n=151)   
Urgent TVR  1.3%  6.6%  p<0.02 
Composite 6.0%  14.6%  p<0.01 
ISAR-2 (44)  (n=201)  (n=200)   
Composite 5.0%  10.5%  p<0.04 
CADILLAC (45) (n=1,052)  (n=1,030)   
Urgent TVR  2.5%  4.4%  p<0.02 
Composite 4.6%  7.0%  p<0.01 
ACE (46)  (n=200)  (n=200)   
Reinfarction 0.5%  4.5%  p<0.01 
Composite 4.5%  10.5%  p<0.02 
TVR=target vessel revascularization. Death, reinfarction, urgent TVR, stroke, and composite end points were evaluated. Only the statistically significant end points are shown. 
Patients in the ADMIRAL, ISAR-2, and ACE Trials were treated with primary stenting. Only half of CADILLAC patients were treated with primary stenting. Current Role of GP IIb/IIIa Inhibitors in AMI  The Open Cardiovascular Medicine Journal, 2010, Volume 4    141 
IIb/IIIa inhibitors for the great majority of AMI patients 
treated with primary PCI. Does this mark the end of an “old 
era” (GP IIb/IIIa inhibitors) and the beginning of a “new era” 
(bivalirudin)? Probably this is the beginning of a more ra-
tionale use of GP IIb/IIIa inhibitors, since certain patients 
may still benefit by their use. UH plus GP IIb/IIIa inhibitors 
still have potential advantages in patients with high clinical 
risk but low bleeding risk. Patients with cardiogenic shock 
may do better with UH plus GP IIb/IIIa inhibitors rather than 
bivalirudin alone. Another group of patients who may bene-
fit from GP IIb/IIIa inhibitors are patients with angiographi-
cally documented large or giant thrombus, patients with stent 
thrombosis, and patients who develop refractory no-reflow 
phenomenon following PCI.  
  There are several limitations of the trial [13] design and 
results that merit careful consideration. First, the limitation 
of an open-label design requires emphasis, as it creates po-
tential for bias. This study design weakens the conclusive-
ness of any analysis of end points, such as bleeding and 
ischemic events. Second, the effect of the administration of 
another antithrombin agent (UH) in approximately 65% of 
the patients in the bivalirudin group shortly before PCI war-
rants consideration. Therefore, bivalirudin was tested as 
monotherapy in only 615 patients. In this group, major car-
diovascular events occurred in 7.2% of the patients, as com-
pared with 5.2% of the patients who received UH plus GP 
IIb/IIIa inhibitor (relative risk, 1.39; 95% CI, 0.85 to 2.28, 
P<0.1). The administration of UH before enrollment to the 
majority of patients in the study mitigates the strength of the 
results with respect to clinical practice in which bivalirudin 
might be used as monotherapy. Third, while the study is rela-
tively large, it is underpowered to evaluate infrequent safety 
endpoints, such as stent thrombosis. Fourth, Abciximab was 
used in only 52% of patients in the UH plus platelet GP 
IIb/IIIa inhibitor group while eptifibatide and tirofiban, 
which have not been extensively evaluated in AMI patients, 
were used in 46% of patients. Also, the comparison of bivali-
rudin with provisional use of GP IIb/IIIa inhibitors vs man-
datory use of GP IIb/IIIa inhibitors in association with UH in 

















Fig. (1). The results of major bleeding in 2 studies with AMI patients treated with primary PCI are shown. The comparison of bivalirudin to 
heparin plus GP IIb/IIIa inhibitors in the HORIZONS trial (Fig. 1A), and, to heparin alone in the study of Bonello L et al (72), (Fig, 1B) is 
depicted. When bivalirudin is compared with heparin, there is only a significant difference in major bleeding in AMI patients undergoing 
PCI only when GP IIb/IIIa inhibitors are systematically added to unfractionated heparin, but not when bivalirudin is compared to heparin 















Fig. (2). The results of major adverse cardiovascular events in 2 studies with AMI patients treated with primary PCI are shown. The com-
parison of bivalirudin to heparin plus GP IIb/IIIa inhibitors in the HORIZONS trial (2A) (13), and, to heparin alone in the study of Bonello L 
et al (2B) is depicted. There was no significant difference in major adverse cardiovascular events in AMI patients undergoing PCI when 
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studies have shown that GP IIb/IIIa inhibitor use is associ-
ated with a reduction in ischemic recurrence at the cost of 
increased bleeding complications. Of importance is that their 
benefit is confined to high-risk patients and, therefore, re-
vealed to be useless and even harmful in low-risk popula-
tions [48, 68]. Thus, the use of systematic GP IIb/IIIa inhibi-
tors in the UH arm may be questionable. It may be question-
able even in AMI patients, especially when, in the real world 
practice, only 20–58% of patients receive them despite their 
potential advantages and according to guidelines [69-71, 54]. 
In addition, the benefit observed with bivalirudin was 
achieved because of the major bleeding complications with 
UH plus GP IIb/IIIa inhibitors. Therefore, what would hap-
pen if we diminish bleeding complications by eliminating 
GP IIb/IIIa inhibitors from the equation? There are some 











Fig. (3). The results of net adverse clinical events in the HORI-
ZONS trial (13) are shown. In the comparison of bivalirudin with 
heparin plus GP IIb/IIIa inhibitors, there was a significant differ-
ence in the net adverse clinical events in AMI patients undergoing 
PCI. That is, the statistical significance was obtained only when 
major bleeding was added to conventional major adverse cardio-
vascular events. 
COMPARISON OF UH WITH BIVALIRUDIN IN AMI: 
THE BEGINNING OF A NEW ERA? 
  There is no randomized trial comparing bivalirudin with 
UH alone in AMI patients undergoing primary PCI. There-
fore, whether or not bivalirudin continues to show similar 
efficacy and reduced bleeding when compared with UH 
without GP IIb/IIIa inhibitor infusion in AMI patients treated 
with primary PCI is an unanswered question by large, ran-
domized trials. However, there are some observational stud-
ies in this setting that can be analyzed.  
 Bonello  L  et al. [72] evaluated the safety and efficacy of 
bivalirudin vs UH when used without GP IIb/IIIa inhibitors 
during primary PCI in AMI patients. The rate of major 
bleeding was identical in the 2 groups (4.1% vs 4.2%, 
P=0.92) (Fig. 1B). Although there was a trend toward less 
hematoma in the bivalirudin group, it did not reach signifi-
cance (3.4% vs 6.7%, P=0.09). The rate of major hematoma 
was identical between the 2 groups as well (0.5% vs 0.6%, 
P=1). There was no difference in the rates of death (1.1% vs 
0.9%, P=1), or major adverse cardiovascular events (2.7% vs 
1.2%, P=0.15) (Fig. 2B) in the bivalirudin and UH groups, 
respectively. No stent thrombosis occurred during in-hospital 
stay. Therefore, the results of this study [72] suggest that in 
primary PCI for AMI, bivalirudin vs UH when used without 
GP IIb/IIIa inhibitors exhibits similar results in terms of 
ischemic and bleeding complications. This could be of major 
interest in patients with high risk of bleedings or low risk of 
ischemic events, which do not receive GP IIb/IIIa inhibitors 
during PCI for AMI. A better ischemic outcome in patients 
with bivalirudin would have been expected due to the lack of 
GP IIb/IIIa inhibitors in the UH group. However, another 
study in AMI patients comparing bivalirudin with UH, also 
reported identical outcomes between the 2 drugs with GP 
IIb/IIIa inhibitors used only as ‘bailout’ in both groups [73].  
 Bittl  JA  et al. [74] compared bivalirudin with UH in pa-
tients undergoing PCI. Although, their results were not ob-
tained from AMI patients, bivalirudin did reduce the inci-
dence of bleeding complications as compared with UH in 
this trial. However, since it was performed more than 15 
years ago, the exclusive use of balloon angioplasty, the lack 
of treatment with clopidogrel, the high dose of UH adminis-
tered, and the outdated regimen of bivalirudin make the trial 
results largely irrelevant to current interventional practice 
[74]. Nevertheles, Kastrati A et al. [75] observed similar 
results in a contemporary PCI setting. They compared bivali-
rudin with UH in stable or unstable angina patients who did 
not have elevated levels of biomarkers, and who were under-
going PCI after having received pretreatment with 600 mg of 
clopidogrel at least 2 h before the procedure. The main find-
ing was that bivalirudin did not provide a net clinical benefit. 
It did not significantly reduce the incidence of the quadruple 
end point (death, myocardial infarction, urgent target-vessel 
revascularization, or major bleeding) compared with UH at 
30 days, although it did significantly reduce the incidence of 
bleeding. Therefore, in the setting of PCI and in the absence 
of GP IIb/IIIa inhibitors, bivalirudin did not offer any bene-
ficial effect in the incidence of the composite end points. The 
benefit observed in the incidence of bleeding in stable or 
unstable angina patients was not observed in AMI patients. 
As we can see in Fig. (1), when bivalirudin is compared with 
UH, there is only a significant difference in major bleeding 
in AMI patients undergoing PCI only when GP IIb/IIIa in-
hibitors are systematically added to UH (Fig. 1A), but not 
when bivalirudin is compared with UH alone without the use 
of GP IIb/IIIa inhibitors (Fig. 1B). In addition, we can see in 
Fig. (2), that when bivalirudin was compared with UH plus 
GP IIb/IIIa inhibitors in the HORIZONS trial [13] (Fig. 2A), 
and, with UH alone in the study of Bonello L et al. [72] (Fig. 
2B), there was no significant difference in major adverse 
cardiovascular events in AMI patients undergoing PCI. 
Moreover, as shown in Fig. (3) in the comparison of bivali-
rudin with UH plus GP IIb/IIIa inhibitors, there was a sig-
nificant difference in the net adverse clinical events in AMI 
patients undergoing PCI in the HORIZONS trial only when 
major bleeding was added to the conventional major adverse 
cardiovascular events. Therefore, it is major bleeding in the 
UH plus GP IIb/IIIa inhibitors group which plays a major 
role in favoring a better outcome and mortality rate in the 
bivalirudin group. Hence, is it the beginning of a new era 
with bivalirudin or is it a welcome back to an old friend UH? 
Although, these questions can only be answered with cer-
tainty with large, double blind, randomized trials in AMI 
patients undergoing PCI, the results of the studies available 
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bivalirudin. For now, in the real world practice, one would 
probably choose a well known cheaper drug that has already 
passed the test of time, UH. 
CONCLUSION 
  Intravenous platelet GP IIb/IIIa receptor antagonists rep-
resent a significant advance in the practice of interventional 
cardiology and have proven to be an important, clinically 
effective adjunct therapy during primary PCI in AMI pa-
tients. Adding platelet GP IIb/IIIa receptor inhibition therapy 
to coronary stenting has demonstrated to have short and 
long-term reduction in ischemic complications, improved 
microcirculatory function and recovery of myocardial func-
tion. Although their utilization has reduced the rate of peri- 
and post-procedural ischemic complications, in parallel, the 
rate of bleeding has increased. In addition, suboptimal levels 
of GP IIb/IIIa receptor antagonists are not only nonprotective 
and prothrombotic, but they also promote inflammation. In 
the light of recent data, there will be a more rational use of 
platelet GP IIb/IIIa inhibitors. They still have potential ad-
vantages in patients with high clinical risk but low bleeding 
risk. Patients with cardiogenic shock may do better with UH 
plus IIb/IIIa inhibitors rather than bivalirudin alone. Another 
group of patients who may benefit from GP IIb/IIIa inhibi-
tors are those with angiographically documented large or 
giant thrombus, patients with stent thrombosis, and patients 
who develop refractory no-reflow phenomenon following 
PCI. 
  Bivalirudin, a direct thrombin inhibitor, was developed as 
an antithrombin agent for patients undergoing PCI with the 
hypothesis that it would reduce bleeding complications 
without compromising the rate of ischemic events compared 
with UH plus GP IIb/IIIa inhibitors. It was demonstrated that 
the strategy of bivalirudin with provisional GP IIb/IIIa in-
hibitors was superior when compared with UH plus system-
atic GP IIb/IIIa inhibitors in regard to reduction in bleeding 
complications without any increase in the rate of ischemic 
events in AMI patients during primary PCI. However, in the 
setting of PCI and in the absence of GP IIb/IIIa inhibitors, 
bivalirudin did not offer any beneficial effect in the inci-
dence of the composite end points when compared with UH. 
The benefit observed in the incidence of bleeding in stable or 
unstable angina patients was not observed in AMI patients. 
Therefore, the results of the studies available until now set 
some doubts in the future widespread use of bivalirudin. For 
now, in real world practice, one would probably choose a 
well known cheaper drug that has already passed the test of 
time, UH. It is rewarding to see that there is so much work 
already done in this field, but there is still a long way to go 
with further investigations to shed more light on yet unan-
swered questions. 
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